Sinopharm India Private Limited - Due diligence report

A 360° intelligence report on Sinopharm Online: trust score, financial health, credit view, compliance, directors, growth and distress signa…

2012-12-10 New Delhi, Delhi Active Unlisted Active Compliant
Share
SI Sinopharm India Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Sinopharm Online — 360° Intelligence Report

Generated from MCA filings & public records
66/100
Trust Score
Moderate

Sinopharm Online is assessed as Moderate with a Trust Score of 66/100. Sinopharm Online is an active private limited foreign company incorporated in india incorporated in 2012, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and high financial risk profile.

Report generated on 16 Jul 2026 from the latest processed filings. Sinopharm India Private Limited snapshot & full profile →

Financial Health › Weak
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Good

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
66/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
64/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
40/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
45/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
50/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 50/100 Moderate
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 64/100 Moderate
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • Litigation present in 2 court forum(s).
  • 1 auditor resignation(s) filed - latest: ASHWANI KUMAR & ASSOCIATES on 2018-03-22.
  • 2 active GST registration(s).
Legal cases on record (2)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
RAJESH SINGH RATHORE 01234567 Director 01/04/2018 6 yrs Approved
LIAO CHUANKUN 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2024 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Sinopharm International Hongkong Limited
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Sinopharm International Hongkong Limited Holding Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 45 · Distress 50
Growth signals & trust indicators
EPFO headcount growing - hiring signal.
Operating for 13+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
Outside liabilities up 38% in a year.
1 auditor resignation(s) on record - review the stated reasons.
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence60/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 3 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment50/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance gaps should be priced into terms.
Investor view48/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 11 events
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
30 Sep 2022
Director ceased
SHI HONGWEI
25 Oct 2021
Director ceased
RAJESH SINGH RATHORE
06 Apr 2021
Director appointed
RAJESH SINGH RATHORE (Director)
30 Mar 2021
Director ceased
LIU LILI
29 Apr 2019
Director ceased
HONG LI
18 Sep 2017
Director ceased
HOUDONG XIN
21 Jul 2014
Director ceased
ZHAO JINGNI
10 Dec 2012
Incorporated
Registered with Roc Delhi
Director appointed
LIAO CHUANKUN (Director)
10

Key Observations

Auto-generated from the data above
Revenue declined 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Net worth is positive.
2 active director(s) / partner(s); board looks stable and experienced.
2 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2024 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Geuis Communication Solutions Private Limited U31900KL2020PTC061837 Kochi, Kerala, India
Kepler Aerospace U74999KA2018PTC114706 Bengaluru, Karnataka, India
Verdure Rf Technologies Private Limited U31909KL2020PTC061835 Kochi, Kerala, India
Fermbox Bio Private Limited U15400KA2022PTC168696 Anekal, Karnataka, India
Airbotix Technology Private Limited U72200HR2022PTC104845 Palam Road, Haryana, India
Manastu Space U73200MH2017PTC293882 Thane, Maharashtra, India
Icga Foundation U73100PN2021NPL197972 Pune, Maharashtra, India
Propharmex U74999TG2017PTC114115 Nacharam, Telangana, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Sinopharm Online before audits and certifications: compliance score 64/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Sinopharm Online: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 45/100, margin trends, ownership structure and peer set for Sinopharm Online - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 66/100, distress signals and MSME payment-delay disclosures - know whether Sinopharm Online pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Sinopharm Online - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Sinopharm Online an active company?

Sinopharm Online has MCA status “Active” with a compliance score of 64/100 (Moderate).

Is Sinopharm Online financially healthy?

Sinopharm Online has a Financial Health Score of 40/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Sinopharm Online?

Its overall Trust Score is 66/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Sinopharm Online?

The ultimate holding entity is Sinopharm International Hongkong Limited. 2 active director(s) are on record.

Does Sinopharm Online have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Sinopharm Online up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 64/100 (Moderate).

Is it risky to lend to Sinopharm Online?

Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.